| ［1］ |
Bray F， Laversanne M， Sung H， et al. Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2024，74（3）：229-263.
|
| ［2］ |
郑荣寿，陈茹，韩冰峰，等.2022 年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志， 2024，46（3）：221-231.
|
| ［3］ |
Ahn S，Woo JW，Lee K，et al.HER-2 status in breast cancer：changes in guidelines and complicating factors for interpretation［J］. J Pathol Transl Med，2020，54（1）：34-44.
|
| ［4］ |
Atallah NM，Alsaleem M，Toss MS，et al.Differential response of HER-2-positive breast cancer to anti-HER-2 therapy based on HER-2 protein expression level［J］.Br J Cancer，2023，129（10）：1692-1705.
|
| ［5］ |
Giuliani S，Ciniselli CM，Leonardi E，et al.In a cohort of breast cancer screened patients the proportion of HER-2 positive cases is lower than that earlier reported and pathological characteristics differ between HER-2 IHC 3+ and HER-2 IHC 2+/HER-2 amplified cases［J］.Virchows Arch，2016，469（1）：45-50.
|
| ［6］ |
Loibl S，Gianni L.HER-2-positive breast cancer［J］.Lancet，2017，389（10087）：2415-2429.
|
| ［7］ |
辛玲，周思成，江泽飞，等.中国118 家三级医院早期HER-2 阳性乳腺癌新辅助治疗现状调查报告［J］.中国实用外科杂志，2024，44（1）：98-102.
|
| ［8］ |
Horimoto Y，Ishizuka Y， Ueki Y， et al.Comparison of tumors with HER-2 overexpression versus HER-2 amplification in HER-2-positive breast cancer patients［J］.BMC Cancer，2022，22（1）：242.
|
| ［9］ |
Krystel-Whittemore M，Xu J， Brogi E， et al. Pathologic complete response rate according to HER-2 detection methods in HER-2-positive breast cancer treated with neoadjuvant systemic therapy［J］. Breast Cancer Res Treat，2019，177（1）：61-66.
|
| ［10］ |
Chen W，Li FX，Lu DL，et al.Differences between the efficacy of HER-2（2+）/FISH-positive and HER-2 （3+） in breast cancer during dualtarget neoadjuvant therapy［J］.Breast，2023，71：69-73.
|
| ［11］ |
朱平，吕泓，柏乾明，等.HER-2 阳性乳腺癌新辅助治疗疗效临床病理学分析［J］.中华病理学杂志，2023，52（9）：907-911.
|
| ［12］ |
岳瑞雪，孔令欣，郝鑫，等.乳腺癌HER-2 蛋白表达水平预测新辅助治疗疗效的真实世界研究［J/CD］.中华临床医师杂志（电子版），2023，17（7）：765-770.
|
| ［13］ |
Xu B，Shen JG，Zhang LW，et al.HER-2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER-2-positive breast cancer［J］.Pathol Res Pract，2022，234：153900.
|
| ［14］ |
Wolff AC，Hammond ME， Schwartz JN， et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidemal growth factor receptor 2 testing in breast cancer［J］.Arch Pathol Lab Med， 2007，31（1）：18-43.
|
| ［15］ |
Wolff AC，Hammond ME，Hicks DG，et al.Recommendations for human epidemal growth factor receptor 2 testing in breast cancer：American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update［J］.Arch Pathol Lab Med， 2014， 138（2）：241-256.
|
| ［16］ |
Wolff AC，Hammond ME，Allison KH，et al.Human epidemal growth factor receptor 2 Testing in breast cancer：American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update［J］. J Clin Oncol，2018，36（20）：2105-2122.
|
| ［17］ |
Wolff AC，Somerfield MR，Dowsett M，et al.Human epidemal growth factor receptor 2 testing in breast cancer： ASCO-College of American Pathologists Guideline Update［J］. J Clin Oncol，2023，41（22）：3867-3872.
|
| ［18］ |
Ma F，Yan M，Li W，et al.Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER-2 positive metastatic breast cancer（PHILA）：randomised， double blind，multicentre，phase 3 trial［J］.BMJ，2023，383：2665.
|
| ［19］ |
Katayama A，Miligy IM， Shiino S， et al. Predictors of pathological complete response to neoadjuvant treatment and changes to postneoadjuvantHER-2 status in HER-2-positive invasive breast cancer［J］.Mod Pathol，2021，34（7）：1271-1281.
|
| ［20］ |
Orrù S，Pascariello E， Pes B， et al. Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER-2-positive breast cancer subtype［J］. Sci Rep，2023，13（1）：12869.
|
| ［21］ |
Yang ZJ，Xin F， Chen ZJ， et al. Real-world data on neoadjuvant chemotherapy with dual-anti HER-2 therapy in HER-2 positive breast cancer［J］. BMC Cancer，2024，24（1）：134.
|
| ［22］ |
Yan H，Xiao H，Zhu J，et al.Association between the HER-2 protein expression level and the efficacy of neoadjuvant chemotherapy in HER-2-positive breast cancer［J］.Cancer Manag Res，2020，12：12715-12722.
|
| ［23］ |
Wang Y，Singh K，Dizon D，et al.Immunohistochemical HER-2 score correlates with response to neoadjuvant chemotherapy in HER-2-positive primary breast cancer［J］.Breast Cancer Res Treat，2021，186（3）：667-676.
|
| ［24］ |
Chen HL， Chen Q， Deng YC. Pathologic complete response to neoadjuvant anti-HER-2 therapy is associated with HER-2 immunohistochemistry score in HER-2-positive early breast cancer［J］.Medicine，2021，100（44）：e27632.
|
| ［25］ |
Zhu J，Jiao D，Wang C，et al. Neoadjuvant efficacy of three targeted therapy strategies for HER-2-positive breast cancer based on the same chemotherapy regimen［J］.Cancers，2022，14（18）：4508.
|
| ［26］ |
Shi Q，Qi X，Tang P，et al. A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER-2-positive breast cancer［J］.Med Comm，2023，4（6）：e435.
|
| ［27］ |
Nielsen TO， Leung SCY，Rimm DL，et al. Assessment of Ki67 in breast cancer： updated recommendations from the international Ki67 in breast cancer working group［J］. J Natl Cancer Inst，2021，113（7）：808-819.
|
| ［28］ |
Perez EA， Reinholz MM， Hillman DW，et al.HER-2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial［J］.J Clin Oncol，2010，28（28）：4307-4315.
|
| ［29］ |
Swain SM，Miles D， Kim SB， et al. Pertuzumab， trastuzumab， and docetaxel for HER-2-positive metastatic breast cancer（CLEOPATRA）：end-of-study results from a double-blind， randomised， placebocontrolled，phase 3 study［J］.Lancet Oncol，2020，21（4）：519-530.
|
| ［30］ |
Pegram M，Jackisch C，Johnston SRD，et al.Estrogen/HER2 receptor crosstalk in breast cancer：combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer［J］.Breast Cancer，2023，9（1）：45-64.
|
| ［31］ |
Modi S，Jacot W， Yamashita T， et al. Trastuzumab deruxtecan in previously treated HER-2-low advanced breast cancer［J］.N Engl J Med，2022，387（1）：9-20.
|
| ［32］ |
Qi X，Shi Q，Xuhong J，et al.Pyrotinib-based therapeutic approaches for HER-2-positive breast cancer：the time is now［J］.Breast Cancer Res，2023，25（1）：113.
|